We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · July 06, 2020

Secukinumab Maintains Superiority Over Ustekinumab in Clearing Skin and Improving Quality of Life in Patients With Moderate to Severe Plaque Psoriasis

Journal of the European Academy of Dermatology and Venereology: JEADV

 

Additional Info

Journal of the European Academy of Dermatology and Venereology: JEADV
Secukinumab Maintains Superiority Over Ustekinumab in Clearing Skin and Improving Quality of Life in Patients With Moderate to Severe Plaque Psoriasis: 52-Week Results From a Double-Blind Phase 3b Trial (CLARITY)
J Eur Acad Dermatol Venereol 2020 May 04;[EPub Ahead of Print], J Bagel, A Blauvelt, J Nia, P Hashim, M Patekar, A de Vera, K Ahmad, B Paguet, S Xia, E Muscianisi, M Lebwohl

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading